Not too long ago, Blade Air Mobility seemed like one of those businesses you would learn about at a dinner party in Manhattan before reading about it in the financial press. In the same way that they used to talk about hailing a cab, people would talk about taking a Blade helicopter to the Hamptons. The experience felt high-end, the branding was crisp, and the stock briefly generated the kind of excitement that comes with businesses that promise to revolutionize daily transportation.
Then everything changed, almost silently. Blade announced in late August 2025 that it was rebranding as Strata Critical Medical and selling Joby Aviation its passenger division. On the exchanges, the ticker BLDE vanished. It was replaced by SRTA. Stock in a medical logistics company was unexpectedly acquired by investors who had been following the helicopter and seaplane story. It’s the type of pivot that, while seemingly simple on paper, can be confusing in real life.
As you watch this happen, you get the impression that management recognized something that the market as a whole had not fully factored in. While the passenger industry was undoubtedly glamorous, the medical transport sector—which involves transporting blood, organs, and urgent medical supplies—had been expanding in the background. More recurring income, less photogenic. The Q4 2025 figures speak for themselves: revenue increased by about 84% year over year to reach 66.79 million. A failing company wouldn’t post that figure.
Even so, it’s difficult to ignore how awkward the transition is. The stock is currently trading in the middle of its 52-week range at 4.92. Since the business isn’t yet profitable, there isn’t a dividend, a clean P/E ratio, or an analyst consensus rating to guide expectations. That’s an odd place to be for a former retail favorite, halfway between forgotten and reinvented.
The story is further complicated by the Joby deal. Uber’s stock recently reached all-time highs, in part due to the announcement that its app will incorporate Joby and Blade services. Blade, or what’s left of Blade, has entered a less crowded room, and his former business is now a part of someone else’s growth story. eVTOLs garner more media attention than medical logistics. However, it covers the expenses.
The market doesn’t seem to have made up its mind about what to do with Strata yet. Due to their disinterest in a medical company they did not sign up for, some longtime BLDE holders probably sold as soon as the rebranding occurred. Others are waiting in silence, wondering if the original Blade’s expansive air-mobility goals can be surpassed by a more compact, targeted operation.
This might be the better course of action. Specialty medical transportation has fewer rivals, closer ties with clients, and demand that is unaffected by weekend travel trends. It’s also possible that Strata loses the storytelling magic that initially made Blade captivating in the absence of the consumer-facing brand.
Blade’s founder, Rob Wiesenthal, has led the company through more reinventions than most CEOs try, turning it from a 2014 startup into a publicly traded company by 2021. Investor patience will be more important in determining whether this most recent one sticks than quarterly revenue surprises. Businesses that change tickers are often overlooked by Wall Street. That forgetting can be a curse at times. For a business looking for its true footing, it can occasionally be the best thing that can happen.
